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Introduction {#sec1}
============

Atopic dermatitis (AD) is a debilitating, chronic inflammatory skin disease affecting 15%--20% of children and up to 10% of adults ([@bib68]). AD is characterized by epidermal hyperplasia, infiltration of innate and adaptive immune cells into the dermis, severe pruritus, and *S. aureus* colonization and superinfections ([@bib16], [@bib68]). The pathogenesis of AD is not well understood, although barrier defects, microbial dysbiosis, genetic predisposition, and environmental factors are thought to contribute to disease.

Transcriptomic analysis of AD patient biopsies has shown enrichment for type 2 immune pathways, the importance of which is highlighted by the efficacy of dupilumab, an IL-4Rα antibody that inhibits IL-4 and IL-13 signaling in AD patients ([@bib57]). However, higher levels of IL-17 and upregulation of the IL-17 signaling pathway have also been observed in AD ([@bib29], [@bib70]). Interestingly, transcriptomic analysis comparing pediatric and adult AD skin biopsies showed more dominant Th17 pathway activation in pediatric patients, which accompanied higher levels of IL-36 expression ([@bib5]). Whether the increase in IL-17 observed in AD is protective or pathological remains to be determined. In inflammatory bowel disease, IL-17A has been shown to be protective for the barrier ([@bib66]), and animal studies similarly suggest that IL-17A and its receptor maintain the skin barrier function ([@bib43], [@bib15]). In addition, IL-17A is postulated to lead to increased anti-microbial production from epithelial cells, which is lower in AD compared with psoriasis ([@bib66]). Consistent with this, recombinant IL-17A given at the time of *S. aureus* challenge rescues the increased inflammation observed in TCRγδ T cell-deficient mice, suggesting a protective role of IL-17A in *S. aureus*-induced skin inflammation ([@bib8]). Furthermore, IL-17A-secreting dendritic cells interacting with the skin microbiota have been shown to be essential to protect the skin from *S. aureus* infections ([@bib43]). These studies suggest a protective role of IL-17A signaling in *S. aureus* colonization, through effects of the commensal bacteria. In contrast, mice lacking IL-17A/F have reduced skin inflammation upon *S. aureus* challenge, implicating a complex role of IL-17A during dysbiosis ([@bib37], [@bib45]). Therefore, the role of IL-17 remains unclear in cutaneous dysbiosis and AD, and further studies are needed to better understand how this cytokine interacts with type 2 inflammation, barrier defects and the microbiota.

There is strong evidence to suggest that *S. aureus* exacerbates AD ([@bib7], [@bib16]). *S. aureus* colonization is observed at a higher frequency in lesional skin, and bacterial load correlates with disease severity ([@bib17]). However, it remains unclear whether *S. aureus* colonization is a cause or a consequence of AD pathology. The heterogeneity of the skin microbiome, which influences *S. aureus* colonization, varies depending on the body site and further complicates investigations into the role of *S. aureus* in AD ([@bib30]). Thus, the question of whether dysbiosis precedes *S. aureus* infection and type 2 immune activation or is secondary to barrier perturbation, resulting in type 2 immune activation, remains unresolved. A recent study showed that dysbiosis can be detected before the onset of inflammatory lesions in children, suggesting that *S. aureus* colonization might be causal to AD ([@bib40]).

The molecular mechanisms leading to *S. aureus* colonization and superinfections in AD patients remains poorly understood. Two recent studies identified an important role for MyD88 signaling in *S. aureus* colonization in mice ([@bib37], [@bib45]). However, whereas [@bib37] suggested that deletion of MyD88 in keratinocyte reduces disease burden, [@bib45] concluded that MyD88 signaling in T cells is sufficient to control *S. aureus* colonization and skin inflammation. Both studies demonstrated IL-17A production downstream of *S. aureus* and that IL-17A/F double-knockout mice have reduced *S. aureus* colonization. These effects are attributed to the secretion of IL-1 family members from keratinocytes, particularly IL-36α. However, these studies are limited by the challenge method of *S. aureus* administration, which does not reflect the natural development of dysbiosis reported in AD. Indeed, a major impediment to our understanding of dysbiosis has been the paucity of mouse models with spontaneous *S. aureus* colonization. Mice lacking the membrane protease ADAM-17 are prone to cutaneous dysbiosis and AD-like skin inflammation, and [@bib28] exploited this observation to demonstrate that *Corynebacterium bovis* induces type 2 inflammation, whereas *S. aureus* exacerbates disease. Nevertheless, several outstanding questions regarding the role keratinocytes and T cells in dysbiosis-induced inflammation and the regulation and cellular sources of IL-17A within the skin remain unsolved.

Here we show that mice with epidermal deletion of JunB/AP-1 exhibit spontaneous skin inflammation with several hallmarks of AD, including high IgE, barrier dysfunction, type 2 inflammation, pruritus, and, critically, spontaneous *S. aureus* colonization. Using this mouse model of cutaneous dysbiosis, we demonstrate a critical role for the adaptive immune system in preventing superinfections and investigate the effect of prophylactic and post-infection antibiotic treatment. Mechanistically, we explored the relationship between *S. aureus* colonization and IL-17A production within the skin and report an important role for JunB in regulating MyD88 expression within keratinocytes. Our data resolve outstanding questions about the role of *S. aureus* in eczematous inflammation and describe a model of spontaneous dysbiosis with chronic inflammation.

Results {#sec2}
=======

Spontaneous *S. aureus* Colonization with AD-like Features Is Observed in *JunB*^*Δep*^ Mice {#sec2.1}
--------------------------------------------------------------------------------------------

We have previously shown that *JunB*^*Δep*^ mice, which have a deletion of *JunB* in K5-expressing cells, exhibit spontaneous chronic skin inflammation with concurrent bone loss through IL-17 signaling ([@bib65], [@bib39], [@bib50], [@bib67], [@bib58]). Upon further characterization of the skin inflammation of these mice, we observed spontaneous *S. aureus* colonization, a hallmark of AD. As mouse models of AD with spontaneous dysbiosis and clinical translatability are currently lacking ([@bib24], [@bib14]), we further investigated the pathophysiological characteristics of skin inflammation in these mice. *JunB*^*Δep*^ mice develop severe skin inflammation with hyperkeratosis and immune cell infiltration by 6 months of age ([Figure 1](#fig1){ref-type="fig"}A). We show that *JunB*^*Δep*^ skin has infiltration of Ym1-positive cells ([Figure 1](#fig1){ref-type="fig"}B), increased TSLP and IL-33 levels in skin ([Figures 1](#fig1){ref-type="fig"}C and 1D), elevated serum IgE ([@bib50]) ([Figure 1](#fig1){ref-type="fig"}E), and significant pruritus ([Figure 1](#fig1){ref-type="fig"}F), all important hallmarks of type 2 inflammation and AD ([@bib69], [@bib44], [@bib3], [@bib6], [@bib11], [@bib72], [@bib64]).Figure 1Spontaneous *S. aureus* Colonization with AD Features Is Observed in *JunB*^*Δep*^ Mice(A) Representative images of H&E staining of skin from control and *JunB*^*Δep*^ mice at 6--7 months of age (n \> 10 per genotype). The yellow scale bar indicates 200 μm.(B) Representative images of Ym1 staining of skin from control and *JunB*^*Δep*^ mice at 6--7 months (n = 4, 4).(C) TSLP levels in skin lysates of control and *JunB*^*Δep*^ mice at 2 (n = 3, 4) and 6--7 months (n = 11, 12).(D) IL-33 levels in skin lysates of control and *JunB*^*Δep*^ mice at 2 (n = 3, 4) and 6--7 months (n = 11, 12).(E) Serum IgE levels of control and *JunB*^*Δep*^ mice at 6--7 months of age (n = 4, 4).(F) Scratch bouts of control and *JunB*^*Δep*^ mice at 6--7 months of age (n = 4, 4).(G) Representative images of Gram staining of skin from control and *JunB*^*Δep*^ mice at 6--7 months (n \> 10 per genotype). Arrows indicate Gram-positive colonies of bacteria. The yellow scale bar indicates 200 μm.(H) Representative images of *S. aureus* immunofluorescence staining of skin from control and *JunB*^*Δep*^ mice at 6--7 months (n \> 10 per genotype). Arrow indicates *S. aureus* colonies.(I) Percentage of *JunB*^*Δep*^ mice positive for *S. aureus* colonization, as assessed by IF for *S. aureus*.(J) Outside-in barrier assay using toluidine blue dye at embryonic day 17.5 (n = 6, 6).

Additionally, Gram staining and immunofluorescence analysis using a specific *S. aureus* antibody showed extensive colonization by Gram-positive *S. aureus* on the skin surface of *JunB*^*Δep*^ mice ([Figures 1](#fig1){ref-type="fig"}G and 1H). We confirmed the identity of the Gram-positive bacteria to be *S. aureus* by growth and fermentation (yellow appearance) on mannitol-salt agar plates, a specific ability of *S. aureus* ([Figure S1](#mmc1){ref-type="supplementary-material"}A), and measured colony-forming units (CFUs) of *S. aureus* ([Figure S1](#mmc1){ref-type="supplementary-material"}B). We also isolated single colonies and carried out PCR with *S. aureus*-specific primers, as well as *S. aureus*-specific gyrase (*gyr*) ([Figure S1](#mmc1){ref-type="supplementary-material"}C). At 6--7 months of age, 100% of *JunB*^*Δep*^ mice had *S. aureus* colonization and skin inflammation, whereas up to 3 months of age, no *S. aureus* colonization was observed ([Figure 1](#fig1){ref-type="fig"}I). To determine the kinetics of dysbiosis in these mice, we carried out Gram staining, coupled with immunofluorescence for keratin 6 as a marker of early inflammatory signals on keratinocytes at 2 days, 1 month, and 3 months post-birth. We observed sporadic Gram-negative colonies with surrounding keratinocytes positively stained for keratin 6, suggesting that prior to the colonization of *S. aureus*, some Gram-negative bacteria might be present in *JunB*^*Δep*^ skin ([Figure S2](#mmc1){ref-type="supplementary-material"}).

To determine the origin of *S. aureus* colonizing the skin of *JunB*^*Δep*^ mice, we carried out PCR analysis for genes that are human specific and rarely found in murine-adapted strains ([@bib22]). These include the immune invasion gene cluster including staphylokinase (*sak*) and staphylococcal complement inhibitor (*scn*) and a human-specific prophase integrase-gene, *sa3int*. In addition, we also analyzed the presence of *mecA*, the gene responsible for methicillin resistance ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Most of the colonies isolated from *JunB*^*Δep*^ skin were positive for *sak*, *scn*, and *sa3int* but were negative for *mecA*, indicating that these bacteria are most likely human adapted but not methicillin resistant. These data suggest that dysbiosis allows *S. aureus*, originating presumably from caretakers, to colonize the skin of *JunB*^*Δep*^ mice.

Barrier defects are a major hallmark of AD pathology and could explain the dysbiosis in *JunB*^*Δep*^ mice ([@bib10], [@bib68]). We therefore evaluated barrier function in *JunB*^*Δep*^ mice. Lesional skin from *JunB*^*Δep*^ mice exhibited significant trans-epidermal water loss, similar to AD ([Figure S1](#mmc1){ref-type="supplementary-material"}D). Levels of loricrin, a component of the cornified cell envelope, were also lost in lesional areas in *JunB*^*Δep*^ mouse skin, consistent with compromised barrier function ([Figure S1](#mmc1){ref-type="supplementary-material"}E). To investigate whether this was due to the absence of JunB or secondary to the skin inflammation, we examined *JunB*^*Δep*^ mouse skin prior to the onset of skin inflammation, specifically during embryonic development and neonatal life. We first evaluated *JunB*^*Δep*^ mice pre-birth, at embryonic day 17.5, when the skin barrier is already formed. Skin barrier function was evaluated using a well-established protocol ([@bib23]) in which embryos were dipped into toluidine blue and assessed for skin penetrance. By this assay, we observed marked toluidine blue indicative of defective barrier function in *JunB*^*Δep*^ mice ([Figure 1](#fig1){ref-type="fig"}J). To assess barrier function post-birth, we measured trans-epidermal water loss. Surprisingly, at 1 and 7 days post-birth, the skin barrier appeared intact in the *JunB*^*Δep*^ mice, suggesting compensatory mechanisms ([Figure S1](#mmc1){ref-type="supplementary-material"}D). Furthermore, we used the biotin diffusion assay ([@bib56]), whereupon fluorescently labeled biotin was injected subcutaneously and the leakage of biotin past the tight junctions was evaluated 1 day post-birth. We observed that the injected biotin co-localized with occludin, staining the tight junctions, suggesting intact inside-out barrier function ([Figure S1](#mmc1){ref-type="supplementary-material"}F). Occludin expression was more prominent in *JunB*^*Δep*^ mice compared with controls, consistent with a compensatory strengthening of tight junction formation. These data suggest that JunB is important for skin barrier function transiently before birth.

Overlapping Transcriptomic Signature with Human AD and Both Type 2 and Type 17 Immune Activation Are Observed in Lesional Skin of *JunB*^*Δep*^ Mice {#sec2.2}
----------------------------------------------------------------------------------------------------------------------------------------------------

Our results indicated that *JunB*^*Δep*^ mice exhibited clinical and histopathological similarities with cutaneous dysbiosis and AD. To determine whether the pathological features of *JunB*^*Δep*^ skin were transcriptionally similar to AD, we carried out RNA sequencing analysis from lesional skin of *JunB*^*Δep*^ mice at 6 months of age. Whole skin was isolated from three *JunB*^*Δep*^ mice and three controls. Total skin was lysed and mRNA extracted and subjected to RNA sequencing. We identified 615 differentially expressed genes (DEGs) with a false discovery rate (FDR) value of \<0.05 between *JunB*^*Δep*^ and controls. These DEGs included genes involved in the immune/inflammatory response, cytokine signaling, keratinization, and regulation of defense responses, consistent with a chronic inflammatory skin phenotype with bacterial colonization, similar to what is observed in AD ([@bib68]) ([Figure 2](#fig2){ref-type="fig"}A). Importantly, several pathways dysregulated in AD were also upregulated in our dataset, including IL-5, IL-23, IL-17, and Jak-Stat signaling pathways ([Figure 2](#fig2){ref-type="fig"}B), noteworthy because many of these pathways are presently under clinical investigation for the treatment of AD ([@bib49]). We then carried out gene set enrichment analysis, comparing the *JunB*^*Δep*^ skin transcriptome with the MADAD (meta-analysis-derived AD) gene signature ([@bib13]), a meta-analysis-derived DEG list from human AD skin. We found a statistically significant positive correlation between the *JunB*^*Δep*^ skin and the MADAD transcriptome ([Figure 2](#fig2){ref-type="fig"}C, left).Figure 2Lesional Skin from *JunB*^*Δep*^ Mice Shows Overlapping Transcriptomic Signature with Human AD, with Both Type 2 and Type 17 Immune Activation(A) Functional annotations derived from RNA sequencing (RNA-seq) analysis of skin from control (n = 3) and *JunB*^*Δep*^ mice (n = 3).(B) Canonical pathways derived from RNA-seq analysis of skin from control (n = 3) and *JunB*^*Δep*^ mice (n = 3).(C) Gene set enrichment analysis (GSEA) showing positive correlations with MADAD (meta-analysis-derived AD) signature, IL-4- and IL-17-responsive genes in keratinocytes.(D) Expression levels of genes implicated in AD pathology, as assessed by qPCR.(E) Correlation of transcriptomic changes of commonly expressed genes in *JunB*^*Δep*^ mice versus *Adam17*^*Δep*^ mice ([@bib73]).

To further investigate the immune responses in these mice, we compared the transcriptomic signature of lesional *JunB*^*Δep*^ skin with publicly available datasets investigating keratinocyte responses to two major pro-inflammatory cytokines present in AD, IL-4, and IL-17A. Strikingly, we observed a statistically significant positive correlation for both of these signatures to *JunB*^*Δep*^ skin, indicating that both type 2 and type 17 immune responses are active in *JunB*^*Δep*^ skin ([Figure 2](#fig2){ref-type="fig"}C, middle and right). A recent report comparing psoriasis and AD showed extensive overlap of these two diseases at the transcriptomic level ([@bib63]). We evaluated whether expression of some of the genes selectively regulated in AD, such as *Duox1*, *Il13ra2*, *Stac2*, as well as other genes implicated in AD pathogenesis in mice or humans such as *Tslp*, *Aqp3*, *Il4ra*, *Nod2*, *Osm*, *Slc4a11*, *Mmp13*, and *Serpinb3* were altered in *JunB*^*Δep*^ mice ([@bib47], [@bib9], [@bib41], [@bib68]). We observed an upregulation of a large proportion of these genes in *JunB*^*Δep*^ mice ([Figure 2](#fig2){ref-type="fig"}D). Moreover, we observed a statistically significant correlation of the transcriptome of *JunB*^*Δep*^ skin with that of ADAM17^*Δep*^ mice, recently published to model the AD transcriptome ([@bib73]) ([Figure 2](#fig2){ref-type="fig"}E).

Collectively, these data show that *JunB*^*Δep*^ mice have skin inflammation with hallmarks of AD both at the phenotypic and at the molecular level.

Skin Inflammation and *S. aureus* Colonization Are Exacerbated in the Absence of Adaptive Immunity {#sec2.3}
--------------------------------------------------------------------------------------------------

We then conducted a detailed analysis of the immune cells in the skin of *JunB*^*Δep*^ mice pre- and post-lesion development, which demonstrated involvement of both the innate and adaptive immune systems. Specifically, we observed increased monocytes, neutrophils, TCRαβ T cells, and TCRγδ T cells in *JunB*^*Δep*^ mice ([Figures 3](#fig3){ref-type="fig"}A--3C). Interestingly, TCRαβ and TCRγδ T cells were increased prior to epidermal hyperplasia, whereas neutrophils and monocytes were increased at later stages of disease ([Figures 3](#fig3){ref-type="fig"}A--3C). Furthermore, group 2 innate lymphoid cells (ILC2s), which produce IL-13 and have been proposed to contribute to the pathogenesis of AD ([@bib27], [@bib54], [@bib55]), were also increased before epidermal hyperplasia, but their numbers normalized as inflammation worsened ([Figure 3](#fig3){ref-type="fig"}C).Figure 3T Cells and ILC2s Infiltrate Skin before the Onset of Overt Inflammation(A and B) Representative flow cytometry plots showing (A) T cell subsets, ILCs, and (B) neutrophils, inflammatory monocytes of pre-lesional (3 months of age; n = 3, 5) and lesional (6 months of age; n = 3, 5) skin in control and *JunB*^*Δep*^ mice.(C) Absolute numbers of immune cell subsets as analyzed using flow cytometry of pre-lesional (3 months of age) and lesional (6 months of age) skin in control and *JunB*^*Δep*^ mice. Markers defining each cell subset are as follows: αβT cells: CD45^+^CD11b^−/\ low^CD3^+^γδTCR^−^; γδT cells: CD45^+^CD11b^−/low^CD3^+^gdTCR^int^; DETC: CD45^+^CD11b^−/low^CD3^hi^gdTCR^hi^; CD2− ILCs: CD45^+^CD90^hi^CD11b^−^CD3^−^γδTCR^−^CD2^−^; Ly6G+ neutrophils: CD45^+^CD11b^hi^CD3^−^gdTCR^−^Ly6G^hi^; Ly6Chi monocytes: CD45^+^CD11b^+^CD3^−^gdTCR^−^Ly6G^−^Ly6C^hi^MHCII−.

The role of T cells in cutaneous dysbiosis and AD pathogenesis remains incompletely understood. Generally, it is considered that type 2 inflammatory cytokine production by T cells enables *S. aureus* colonization and that *S. aureus*-derived superantigens activate T cells in the skin to promote inflammation ([@bib1]). In contrast, IL-17 production by T cells is likely to serve anti-*S. aureus* function, partially via upregulation of anti-microbial proteins ([@bib8]). To investigate whether T cells exacerbated or ameliorated inflammation in *JunB*^*Δep*^ mice with spontaneous dysbiosis, we crossed these mice to *Rag1*^--/--^ mice, which lack mature T and B cells. Strikingly, *JunB*^*Δep*^*Rag1*^--/--^ mice developed exacerbated skin inflammation at an earlier time point with higher *S. aureus* load ([Figure 4](#fig4){ref-type="fig"}A). In ∼15% of *JunB*^*Δep*^*Rag1*^--/--^ mice, *S. aureus* caused superinfections and botryomycosis (data not shown). We observed an increase in the number of mast cells by toluidine blue staining and Langerhans cells by langerin staining in *JunB*^*Δep*^*Rag1*^--/--^ skin ([Figure 4](#fig4){ref-type="fig"}A). Importantly, we observed equal or higher amounts of pro-inflammatory cytokines in the 3-month-old *JunB*^*Δep*^*Rag1*^--/--^ (lesional skin) mice compared with *JunB*^*Δep*^ mice (pre-lesional skin), including elevated IL-4, IL-1β, and IL-22, as well as alarmins and the anti-microbial proteins beta-defensin 14, Lipocalin-2 (Lcn-2), and S100A9 ([Figure 4](#fig4){ref-type="fig"}B), confirming that the inflammatory mediators appear earlier in *JunB*^*Δep*^*Rag1*^--/--^ compared with *JunB*^*Δep*^ *mice*.Figure 4Skin Inflammation and *S. aureus* Colonization Are Exacerbated in the Absence of Adaptive Immunity(A) Representative images of Gram, langerin, and toluidine blue of skin in *JunB*^*Δep*^ and *JunB*^*Δep*^*Rag1*^--/--^ mice at 3 months of age (n = 6, 6). The yellow scale bar indicates 200 μm.(B) Relative expression levels of pro-inflammatory cytokines in the skin of *JunB*^*Δep*^ and *JunB*^*Δep*^*Rag1*^--/--^ mice at 3 months of age compared with controls (n = 3, 5, 6).(C) Serum IL-17A levels in *JunB*^*Δep*^ and *JunB*^*Δep*^*Rag1*^--/--^ mice at 3 months of age compared with controls (n = 7, 11, 9).(D) Representative flow cytometry plots with GFP+ cells overlaid in the skin of *JunB*^*Δep*^ and *JunB*^*Δep*^*Rag1*^--/--^ mice at 4 months of age compared with controls. The cells shown are gated on CD45^+^CD90^+^CD11b^−^.(E) Heatmaps showing IL-17A expression on t-SNE plots from total IL-17A-eGFP+ cells. The map on the right is created using conventional gating, as described in [Figure 2](#fig2){ref-type="fig"}.

These data suggest that T cells are important for controlling *S. aureus* in *JunB*^*Δep*^ mice, presumably via IL-17A production, even though we cannot exclude the role of B cells, also absent in *Rag1*^*−/−*^ mice. Consistent with this hypothesis, *JunB*^*Δep*^ mice had higher serum IL-17A levels compared with *JunB*^*Δep*^*Rag1*^--/--^ mice ([Figure 4](#fig4){ref-type="fig"}C). IL-17A can be produced by both TCRαβ T cells and TCRγδ T cells, as well as ILC3s ([@bib61], [@bib59], [@bib12]). To determine the cell type(s) responsible for IL-17A production in *JunB*^*Δep*^ mice, we crossed these mice to an *Il17a*-eGFP reporter mouse ([@bib35]). In these mice, cells expressing *Il17a* express GFP, which is readily detectable using flow cytometry. We observed basal *Il17a*-eGFP expression by skin-resident TCRγδ T cells but not TCRαβ T cells in control mice and a massive upregulation of *Il17a* expression by both TCRγδ and TCRαβ T cells (Th17 cells) in *JunB*^*Δep*^ skin ([Figure 4](#fig4){ref-type="fig"}D).

IL-17 can also be produced by ILC3s ([@bib12]). Cytokine production by ILC3s has been shown to be capable of compensating for the absence of T cells to prevent colonic infection with *Citrobacter rodentium* ([@bib52]). We observed only modest *Il17a* expression in skin ILCs in (Rag-sufficient) *JunB*^*Δep*^ skin ([Figure 4](#fig4){ref-type="fig"}E). However, we were interested in determining whether this changed in the absence of T cells. We therefore examined IL-17A expression in *JunB*^*Δep*^*Rag1*^--/--^ mice on a *Il17a*-eGFP reporter background. In these mice, we observed *Il17a*-eGFP expression only in ILCs, presumably ILC3s. However, these *Il17a*^+^ ILC3s were substantially less abundant than *Il17a*^+^ T cells in (Rag-sufficient) *JunB*^*Δep*^ skin ([Figure 4](#fig4){ref-type="fig"}C). This was confirmed in unbiased t-Distributed Stochastic Neighbor Embedding (t-SNE) analysis of the *Il17a*-eGFP^+^ cells in *JunB*^*Δep*^ and *JunB*^*Δep*^*Rag1*^--/--^ mice, which indicated an increase in the number of GFP^+^ ILC3s in *JunB*^*Δep*^*Rag1*^--/--^ mice relative to *JunB*^*Δep*^ mice that was nevertheless substantially short of the T cell response observed in Rag-sufficient mice ([Figure 4](#fig4){ref-type="fig"}E).

To determine whether ILC3s can compensate for T cells in a setting where IL-17A is potently induced, we topically administered imiquimod (IMQ) to Rag-sufficient or *Rag1*^--/--^ mice for 5 days. We observed *Il17a*-eGFP expression in Th17, TCRγδ, and ILCs upon IMQ administration to Rag-sufficient mice ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). However, in *Rag1*^--/--^ mice, the *Il17a*-eGFP expression in ILC3s was not increased. Thus, this limited capacity for *Il17a*^+^ ILC3s to compensate for T cells was observed in both settings (i.e., *JunB*^*Δep*^*Rag1*^--/--^ and following topical treatment with IMQ, a potent stimulator of IL-17) ([Figure S3](#mmc1){ref-type="supplementary-material"}C).

In summary, in the absence of the adaptive immune system, *S. aureus* colonization and skin inflammation were accelerated and exacerbated, and this correlated with diminished IL-17A production within the skin.

Prophylactic Antibiotics Reduce Skin Inflammation before Microbial Dysbiosis {#sec2.4}
----------------------------------------------------------------------------

Antibiotics are often used in AD patients with limited efficacy, hypothesized to be due to lack of specificity to *S. aureus* and possibly lack of effect on *S. aureus* killing ([@bib71]). Indeed, understanding of the role of microbial dysbiosis in AD is confounded by variable response to antibiotic treatment. Thus, whether *S. aureus* colonization is causal or a consequence of type 2 inflammation remains to be answered. To investigate the pathological role of *S. aureus* colonization in the skin inflammation observed in *JunB*^*Δep*^ mice, we treated these mice with antibiotics pre- and post-*S. aureus* colonization. We used the *JunB*^*Δep*^ mice crossed to *Il17a*-GFP reporter mice to analyze IL-17A responses. Mice were put on antibiotics in their drinking water at weaning and observed until their non-antibiotic-treated counterparts developed skin inflammation (6--7 months). Importantly, at 1 month of age, no colonization of *S. aureus* was observed, even though some colonies of Gram-negative bacteria were observed in *JunB*^*Δep*^ skin (data not shown). We observed a strong amelioration of the skin inflammatory phenotype in *JunB*^*Δep*^ mice treated with antibiotics, with reduced hyperkeratosis and decreased immune cell infiltration ([Figure 5](#fig5){ref-type="fig"}A). Gram staining identified decreased to non-detectable Gram-positive colonization on the skin of mice treated with antibiotics ([Figure 5](#fig5){ref-type="fig"}A). Swabs taken from the skin of mice and grown on blood agar plates showed reduced *S. aureus* burden in mice treated with antibiotics ([Figure 5](#fig5){ref-type="fig"}B). Detailed flow cytometry analysis of the skin of these mice demonstrated decreased IL-17A-producing γδT cells as well as Th17 cells and ILCs ([Figures 5](#fig5){ref-type="fig"}C--5E). We also observed a drop in the number of neutrophils and inflammatory macrophages in the skin of *JunB*^*Δep*^ mice treated with antibiotics before the development of skin inflammation and *S. aureus* colonization. These data suggest that *S. aureus* colonization contributes to the development of chronic skin inflammation in *JunB*^*Δep*^ mice.Figure 5Prophylactic Antibiotics Reduce Skin Inflammation(A) Representative H&E and Gram staining images of control and *JunB*^*Δep*^ mice with or without prophylactic antibiotics (UT: n = 4, 3; Ab: n = 2, 5). The blue scale bar indicates 200 μm.(B) Blood agar plates from swabs from control and *JunB*^*Δep*^ skin with or without prophylactic antibiotic treatment and quantification of total bacterial load on skin.(C) Number of infiltrating immune cells into the skin of control and *JunB*^*Δep*^ mice with or without prophylactic antibiotics as analyzed using flow cytometry. Gating strategy as described in [Figure 2](#fig2){ref-type="fig"}.(D) Representative flow cytometry images of IL-17A expressing T cells of control and *JunB*^*Δep*^ mice with or without prophylactic antibiotics.(E) Representative flow cytometry images of IL-17A expressing ILCs of control and *JunB*^*Δep*^ mice with or without prophylactic antibiotics.

Antibiotic Treatment Post-development of Skin Inflammation Does Not Provide Therapeutic Benefit {#sec2.5}
-----------------------------------------------------------------------------------------------

Because we observed decreased skin inflammation when mice were treated with antibiotics before skin inflammation and dysbiosis occurred, we then moved to a therapeutic model. *JunB*^*Δep*^ *Il17a*-GFP reporter mice were put on antibiotics in their drinking water after the development of skin inflammation at 6 months for either 1 or 2 weeks, prior to immunological assessment as above.

t-SNE analysis, as well as conventional flow cytometry analysis, of the lymphoid and the myeloid cells in the skin of mice upon either 1 or 2 weeks of antibiotic treatment illustrated a transient decrease in the total number of αβ and γδT cells, with no major changes in neutrophil and monocyte numbers ([Figure 6](#fig6){ref-type="fig"}A; [Figures S4](#mmc1){ref-type="supplementary-material"} and [S5](#mmc1){ref-type="supplementary-material"}). With regard to the IL-17A-producing cells, at 1 week, the effect of antibiotics was minimal, with a slight trend towards reduced numbers of *Il17a*-GFP^+^ γδT cells and ILC3s in skin of mice treated with antibiotics ([Figures 6](#fig6){ref-type="fig"}A and 6B). At 2 weeks post-antibiotics, we observed a statistically significant decrease in the number of *Il17a*-GFP^+^ γδT cells ([Figures 6](#fig6){ref-type="fig"}A and 6B; [Figure S4](#mmc1){ref-type="supplementary-material"}). Unexpectedly, the number of skin neutrophils was increased 1 week post-antibiotics, but this trend did not continue 2 weeks post-antibiotics ([Figure 6](#fig6){ref-type="fig"}B; [Figure S4](#mmc1){ref-type="supplementary-material"}). αβT cell numbers were increased in the skin-draining lymph nodes of these mice, whereas no changes were observed in the number *Il17a*-GFP^+^ γδT cells, Th17 cells, neutrophils, or monocytes ([Figure S6](#mmc1){ref-type="supplementary-material"}). Swabs from mice grown on blood agar plates showed a general reduction of *S. aureus* colonies upon antibiotic treatment, although the extent of reduction was variable ([Figure 6](#fig6){ref-type="fig"}C). To determine whether antibiotic resistance might account for the variability observed in the different mice, we subjected another set of *JunB*^*Δep*^ mice at 6 months of age to antibiotics for 3 weeks, following the bacterial burden over time. Interestingly, not all mice behaved the same upon antibiotic treatment. Although some mice were sensitive to antibiotics, others were completely resistant ([Figure S7](#mmc1){ref-type="supplementary-material"}A). Flow cytometric analysis at the 3 week time point showed that mice that were sensitive to antibiotics had smaller numbers of γδT cells, αβT cells, ILCs, neutrophils, and inflammatory monocytes in the skin compared with resistant mice ([Figure S7](#mmc1){ref-type="supplementary-material"}B). Of note, these short antibiotic treatment schemes did not lead to any discernable macroscopic changes in the clinical features of these mice (data not shown). These data suggest that IL-17A-producing cells are linked to the bacterial burden, and antibiotic treatment post-dysbiosis leads to a transient induction in macrophage and neutrophil numbers. However, resistance occurs in a subset of mice upon continued antibiotic administration. Additional studies will be needed to delineate the differences in the microbiota composition of the mice showing antibiotic sensitivity versus resistance.Figure 6Antibiotic Treatment Post-development of Skin Inflammation Does Not Provide Therapeutic Benefit(A) t-SNE plots showing the distribution of lymphoid (top) and myeloid (bottom) cells in *JunB*^*Δep*^ mice with or without 1 and 2 weeks of antibiotics compared with controls as analyzed using flow cytometry. Maps on the left were made using conventional gating as described in [Figure 2](#fig2){ref-type="fig"}. UG, ungated (control \[Ctrl\], n = 6; *JunB*^*Δep*^ UT, n = 5; 1 week, n = 4; 2 weeks, n = 5).(B) Number of infiltrating immune cells into the skin of *JunB*^*Δep*^ mice with or without 1 and 2 weeks of antibiotics compared with controls as analyzed by conventional flow cytometry.(C) Blood agar plates from swabs from *JunB*^*Δep*^ mice with or without 1 and 2 weeks of antibiotics compared with controls as analyzed using flow cytometry and quantification of total bacterial load on lesional skin.

MyD88 Signaling Is Upregulated in *JunB*^*Δep*^ Skin, and MyD88 Is Upregulated in JunB-Deficient Keratinocytes {#sec2.6}
--------------------------------------------------------------------------------------------------------------

IL-36α has recently been implicated to be upregulated by *S. aureus* and orchestrate the downstream IL-17 signaling events ([@bib37], [@bib45]). Consistent with this, we observed elevated *Il36a* and *Il36b* and *Il36g* expression levels in lesional skin of *JunB*^*Δep*^ mice ([Figure 7](#fig7){ref-type="fig"}A). To determine whether the trigger for the elevated *Il36a* levels was due to microbial signals or deletion of *JunB*, we turned to *in vitro* keratinocyte cultures. Specifically, keratinocytes isolated from *JunB*^*lox/lox*^ mice were subjected to infection by adenoviruses expressing Cre recombinase and empty adenoviruses as control. *JunB*-deficient and *JunB*-sufficient keratinocytes were then exposed to microbial antigens produced from supernatants derived from swabs applied onto *JunB*^*Δep*^ lesional skin ([Figure 7](#fig7){ref-type="fig"}B). Deletion of *JunB* in keratinocytes *in vitro* led to higher *Il36a* relative to controls, which was not further enhanced by microbial signals ([Figure 7](#fig7){ref-type="fig"}C). Expression of genes encoding several alarmins, such as the S100A9 and Lcn-2, as well as inflammation-associated chemokines Cxcl1, Cxcl2, and Ccl2 were upregulated in keratinocytes upon incubation with the microbial supernatant, and these responses were further upregulated in keratinocytes lacking JunB ([Figure 7](#fig7){ref-type="fig"}C).Figure 7MyD88 Signaling Is Upregulated in *JunB*^*Δep*^ Skin, and MyD88 Is Upregulated in JunB-Deficient Keratinocytes(A) Relative expression levels of il1f6 (Il36α), Il1f8 (Il36β), and Il1f9 (Il36γ) in the lesional skin of *JunB*^*Δep*^ mice compared with controls (n = 5, 6).(B) Schematic diagram depicting the experimental design for (C) and (E).(C) Relative expression levels of chemokines and alarmins upon JunB deletion in *JunB*^*lox/lox*^ keratinocytes using adenoviruses expressing Cre recombinase with or without supernatant (S/N) derived from swabs from lesional skin of *JunB*^*Δep*^ mice (n = 3, 3, repeated three separate times).(D) MyD88 and its downstream genes are significantly regulated in the transcriptome of *JunB*^*Δep*^ skin.(E) Western blot using control or *JunB*^*Δep*^ keratinocytes upon S/N administration (as described in B) for indicated time points. MyD88 levels and vinculin (as loading control) are shown.(F) Representative images of MyD88 levels by immunohistochemistry in skin from control or *JunB*^*Δep*^ mice. Arrows indicate examples of MyD88-positive keratinocytes. The yellow scale bar indicates 100 μm.(G) Upon loss of keratinocyte expression of JunB, MyD88 levels are increased. Together with microbial products, increased MyD88 levels lead to increased alarmin/chemokine expression, starting a cascade of inflammatory response, including increased IL-17A production from Th17, γδT cells, and ILC3s. In a *Rag1*^*−/−*^ background, IL-17A is expressed by ILC3s, but skin inflammation is exacerbated in the absence of the adaptive immune system.

As MyD88 is downstream of IL-36 signaling, we checked whether MyD88-mediated signaling is upregulated in *JunB*^*Δep*^ lesional skin. MyD88 was predicted as one of the upstream regulators of the global changes in gene expression by Ingenuity Pathway Analysis (IPA), and many genes downstream of MyD88 were significantly regulated ([Figure 7](#fig7){ref-type="fig"}D). Moreover, an increase in MyD88 protein levels was observed in keratinocytes lacking JunB, which was not further increased upon microbial signals ([Figure 7](#fig7){ref-type="fig"}E). *In vivo*, we observed increased levels of MyD88 protein in keratinocytes and immune cells in *JunB*^*Δep*^ skin, as assessed by immunohistochemistry ([Figure 7](#fig7){ref-type="fig"}F). These data suggest that JunB negatively regulates IL-36 and MyD88 levels in keratinocytes, which have been shown to be important for the colonization of *S. aureus* on skin ([Figure 7](#fig7){ref-type="fig"}G).

Discussion {#sec3}
==========

In this study, we show that epithelial expression of JunB is a gatekeeper of immune-microbiota interactions, and its loss leads to chronic skin inflammation with spontaneous *S. aureus* colonization. *JunB*^*Δep*^ mice share many pathological aspects of AD, including but not limited to type 2 and type 17 immune responses, elevated IgE levels, barrier dysfunction, and, importantly, spontaneous *S. aureus* colonization.

We took advantage of this mouse model to address some unanswered questions, such as the role of T cells in controlling *S. aureus* and the role of IL-17A in AD with *S. aureus* colonization.

IL-17, a potent pro-inflammatory cytokine, is central to the pathogenesis of psoriasis, and IL-17 blockers have shown unprecedented success in the treatment of this disease ([@bib34], [@bib31], [@bib53]). IL-17 is produced by T helper cell subset Th17, as well as γδT cells and ILC3s. IL-17 is upregulated in AD skin, albeit at lower levels compared with psoriasis, but its role in AD remains unclear ([@bib21]). Whether IL-17A has a protective or pathogenic role in pediatric or adult AD remains to be understood. Elucidating the role of IL-17A in AD is important, as blockade of IL-17A and its upstream cytokine IL-23 is currently being tested in clinical trials for AD ([@bib49]).

ILCs have been proposed to play a protective role in *S. aureus*- and pneumonia-induced inflammatory processes ([@bib51], [@bib19]), and ILC2s have been shown to accumulate in the skin of AD patients ([@bib27], [@bib55]). Kinetic analysis of the ILCs in the skin of *JunB*^*Δep*^ mice showed a transient increase in the number of ILCs before the appearance of overt skin inflammation and *S. aureus* colonization. However, there were no differences in the number of ILCs infiltrating the lesional skin, whereas an increased number of IL-17A+ ILCs (ILC3s) were observed. In the presence of T cells, we observed a minor contribution of ILC3s to the IL-17A-producing population. However, in *Rag1*^--*/--*^ mice, the number of IL-17A expressing ILC3s increased, albeit not to sufficient levels to compensate for the T cell deficit. These data suggest that ILC3s are only partially redundant with T cells in the skin. Future studies are needed to determine whether ILC3s are present in AD skin and the level of plasticity observed between group 2 and group 3 ILCs in AD.

Barrier defects, caused for example by filaggrin mutations, have been linked to the pathogenesis of AD. However, it is important to note that about 40% of individuals with filaggrin mutations never show AD symptoms ([@bib46]). Thus, it is likely that barrier defects are not sufficient to lead to the development of AD, and a second hit, possibly from the environment, is needed to induce the inflammatory responses in skin. Along with these findings in humans, the filaggrin-deficient mice, which have a clear skin barrier defect, do not develop inflammation until 20--28 weeks of age ([@bib48]). Moreover, filaggrin defects are shown not to be sufficient to induce spontaneous AD-like lesions in many reports. Most studies add an allergen such as house dust mite to induce inflammation in mice with filaggrin defects ([@bib42], [@bib26]). We hypothesize that in the *JunB*^*Δep*^ mice, the early-life barrier dysfunction renders the skin more sensitive to allergens and microbes, in this case, particularly *S. aureus*.

The dysbiosis observed in *JunB*^*Δep*^ mice likely precedes inflammation, as prophylactic antibiotic treatment restricted the development of skin inflammation and strongly ameliorated epidermal hyperproliferation. In contrast, antibiotic treatment after *S. aureus* colonization demonstrated variable efficacy in *JunB*^*Δep*^ mice. This mirrors the clinical reality of AD, in which antibiotic treatment often demonstrates little to no success in controlling disease. The reason for the disparate efficacy of prophylactic versus therapeutic antibiotic treatment remains unknown. This may reflect antibiotic access or efficacy within inflamed skin and/or active drug resistance mechanisms in established *S. aureus*. Alternatively, there may be other species of antibiotic-susceptible bacteria that are necessary for *S. aureus* colonization but dispensable once colonization has established. In *JunB*^*Δep*^ mice, we detected small amounts of Gram-negative bacteria at early time points, before the colonization of *S. aureus*, that did not correlate with disease. Thus, although we cannot formally exclude that other bacteria might initiate dysbiosis in these mice, because of their low abundance and variability, they are unlikely to be directly responsible for the observed pathology. With growing advances in microbiome sequencing technology, these questions will be addressable in the near future.

The mechanisms by which *S. aureus* is sensed by different cell types in the skin and the downstream signaling pathways activated have recently gained a lot of attention ([@bib4]). Pattern recognition receptors such as Toll-like receptors (TLRs), as well as NOD receptors, have been shown to contribute to the initial recognition of bacterial antigens. Activation of the TLRs leads to NF-κB activation via MyD88 signaling ([@bib25]). Mutations in TLR2 decreasing intracellular signaling have been linked to higher *S. aureus* load and disease severity in AD ([@bib2]). However, the mechanisms leading to susceptibility to develop AD are still not well understood. An important finding of our study is the observation that JunB loss in keratinocytes is sufficient to drive skin inflammation, likely through a combination of dysbiosis due to barrier dysfunction and the enhanced responses to dysbiosis. Mechanistically, JunB negatively regulates MyD88, because its deletion in keratinocytes *in vitro* is sufficient for upregulation of many chemokines and alarmins, including IL-36α, previously reported to be secreted from keratinocytes upon *S. aureus* colonization ([@bib37]). The transcriptomic profile of the *JunB*^*Δep*^ skin shows regulation of several pathways such as TLR signaling, as well as many anti-microbial molecules, such as Lcn-2. Interestingly, deletion of p65 in keratinocytes in *JunB*^*Δep*^ mice led to exacerbated skin inflammation with higher *S. aureus* load, highlighting that the NF-κB pathway in keratinocytes is protective for skin homeostasis in the presence of *S. aureus* (data not shown). These data suggest that loss of JunB in keratinocytes is a susceptibility factor for the development of *S. aureus*-induced skin inflammation. Unfortunately, there are no protein data available from patients with overt *S. aureus* colonization and superinfections compared with non-overt/limited *S. aureus* colonization to determine the co-localization of bacterial colonies and keratinocyte JunB expression. A prospective study making use of biopsies without prior desterilization conditions will be necessary to answer this question.

In summary, we show that JunB is a critical transcription factor in immune-microbiota crosstalk and that its loss is detrimental for skin immunity. These findings highlight the essential role of keratinocytes, an underestimated cell type in skin inflammation. We also show that JunB negatively regulates MyD88 in keratinocytes. These mice are an ideal model to further investigate the role of the microbiota and *S. aureus* in AD, as they represent the natural evolution of skin inflammation resembling AD.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**S. aureus antibodyAbcamCat\#ab20920; RRID: [AB_445913](nif-antibody:AB_445913){#interref65}Loricrin antibodyCovanceCat\#PRB-145P; RRID: [AB_10064155](nif-antibody:AB_10064155){#interref70}MyD88 antibodyCell SignalingCat\#D80F5; RRID: [AB_10547882](nif-antibody:AB_10547882){#interref75}CD45-APCCy7BiolegendCat\#103115; RRID: [AB_312980](nif-antibody:AB_312980){#interref80}CD3-PEBiolegendCat\#100205; RRID: [AB_312662](nif-antibody:AB_312662){#interref85}gdTCR-BV421BiolegendCat\#118119; RRID: [AB_10896753](nif-antibody:AB_10896753){#interref90}CD90.2-APCBD PharMingenCat\#553007; RRID: [AB_398526](nif-antibody:AB_398526){#interref95}CD11b-PerCPCy5.5BD PharMingenCat\#550993; RRID: [AB_394002](nif-antibody:AB_394002){#interref100}CD2-PeCy7BiolegendCat\#100113; RRID: [AB_2563091](nif-antibody:AB_2563091){#interref105}MHCII-Pacific BlueBiolegendCat\#107619; RRID: [AB_493528](nif-antibody:AB_493528){#interref110}Ly6C-APCBD BiosciencesCat\#560595; RRID: [AB_1727554](nif-antibody:AB_1727554){#interref115}Ly6G-PEBD BiosciencesCat\#561104; RRID: [AB_10563079](nif-antibody:AB_10563079){#interref120}CD11b-PeCy7BD PharMingenCat\#552850; RRID: [AB_394491](nif-antibody:AB_394491){#interref125}**Chemicals, Peptides, and Recombinant Proteins**Aldara 5% creamMedaN/AStreptavidin-AF488InvitrogenS11223**Deposited Data**RNaseq data from skin from control and JunB^Δep^ miceThis paperGSE136657**Experimental Models: Organisms/Strains**Mouse: JunBΔep: B6.129P2-Junbtm3Wag/J crossed to K5-CreN/AN/AMouse: Rag1−/−: B6.129S7-*Rag1*^*tm1Mom*^/JN/AN/AMouse: IL-17A-eGFP: C57BL/6-*Il17a*^*tm1Bcgen*^/JN/AN/A**Oligonucleotides**Oligos for q-RT-PCRSee [Table S1](#mmc1){ref-type="supplementary-material"} for oligo sequencesN/A**Software and Algorithms**Nextpresso[@bib18]<http://bioinfo.cnio.es/nextpresso/>FastQC (v 0.11.0)<https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>Bowtie (v 1.0.0 70)[@bib32]<http://bowtie-bio.sourceforge.net/bowtie2/index.shtml>SAMtools (v 0.1.19 71)[@bib36]<http://samtools.sourceforge.net/>GSEA v(2.08)[@bib60]<http://software.broadinstitute.org/gsea/index.jsp>TopHat (v 2.0.10 69)[@bib27]<https://ccb.jhu.edu/software/tophat/index.shtml>

Lead Contact and Materials Availability {#sec4.2}
---------------------------------------

Further information may be directed to and will be fulfilled by the Lead Contact, Özge Uluçkan (<ozge.uluckan@novartis.com>). This study did not generate new unique reagents.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Mice {#sec4.3.1}

All mouse experiments were performed in accordance with local and institutional regulations/licenses. The generation of the *JunB*^*Δep*^ mice has previously been described ([@bib39]). *JunB*^*Δep*^ mice were backcrossed to C57B/6 for at least 7 generations. Mice of both sexes were included in the study, since no gender differences were observed. *Il17a*-eGFP (C57BL/6-*Il17*a^tm1Bcgen/J^) mice, originally generated at Biocytogen and previously described ([@bib35]), were purchased from Jackson Laboratory.

Method Details {#sec4.4}
--------------

### Histological analyses {#sec4.4.1}

Tissues were fixed in phosphate-buffered saline--buffered 3.7% formalin. H&E staining was performed according to standard procedures (Sigma). Immunohistochemistry was performed with Elite ABC Kit (Vectastain) and DAB (Vector Laboratories). Immunofluorescence was performed as described previously ([@bib20]). In short, tissues were fixed in phosphate-buffered saline--buffered 3.7% formalin. Primary antibodies were incubated overnight at 4C and secondary antibodies for 1 hour at RT. Counterstainings were performed with 4′,6-diamidino-2-phenylindole (Sigma) and sections were mounted using Prolong Gold anti-fade reagent (ThermoFisher).

Gram staining was carried out using provider's instructions (Sigma). Toluidine Blue staining was performed using standard protocols. *S. aureus* antibody was purchased from Abcam (ab20920), Loricrin and Keratin 6 antibodies from Covance (PRB-145P), and MyD88 antibody (D80F5) from Cell Signaling. Secondary antibodies were purchased from Invitrogen and used at 1:250 dilution.

### Barrier analysis {#sec4.4.2}

Trans-epidermal water loss was measured using Tewameter TM300 from Courage-Khazaka.

Outside-in Toludine blue assay was carried out as described in [@bib23] and briefly embryos isolated at embryonic day E17.5 were incubated in methanol for 5 mins, rinsed in PBS, then incubated in 0.1% Toluidine Blue for 5 mins. Embryos were kept in PBS and photographed immediately afterward.

Inside-out biotin diffusion assay was carried out as described in [@bib56]. 10 mg/ml EZ-Link sulfo-NHS-LC-biotin (Pierce Chemical Co., Rockford, IL) in PBS containing 1 mM CaCl~2~ was injected intradermally into the back skin of 1-day old mice. After 30 minutes, mice were sacrificed and the skin was embedded in Tissue-Tek and snap-frozen on dry ice. Paraformaldehyde-fixed cryosections were stained with Occludin antibody (Thermo-Fisher-Zymed (40-6100)). Sections were then stained with streptavidin-AF488 (Invitrogen), a AF555-labeled secondary antibody to detect occludin and DAPI to visualize the nuclei.

### Flow cytometry {#sec4.4.3}

Skin from mice was isolated and subjected to mild digestion with liberase (Roche™), and mechanically disrupted using GentleMACS Dissociator (Miltenyi). The single cell suspension was stained with either CD45-APCCy7 (Biolegend), CD3-PE (Biolegend), gdTCR-Brilliant Violet 421 (Biolegend), CD90.2-APC (BD PharMingen), Cd11b-PerCPCy5.5 (BD PharMingen) and CD2-PECy7 (Biolegend), or CD45-APCCy7 (Biolegend), MHCII-PacBlue (Biolegend), Ly6C-APC (BD PharMingen), Ly6G-PE (BD PharMingen), CD11b-PECy7 (BD PharMingen). Samples were collected in a FACS CANTO II (BD, San Jose CA) equipped with 488nm, 640nm and 405nm lines. We used pulse processing to exclude cell aggregates and live/dead fixable dye Aqua (Invitrogen) to exclude dead cells. At least 100,000 alive single events were collected; all data were analyzed using FlowJo v10 (Treestar, Oregon).

### Antibiotic administration {#sec4.4.4}

Enrofloxacin (Baytril) (0.025%) was added to the drinking water either at weaning (for prophylactic experiments) or at 6 months of age for 1, 2 or 3 weeks and changed every 3 days. For the prophylactic experiments, enrofloxacin was kept in the drinking water thoughout the lifetime of the mice.

### Bacterial analysis {#sec4.4.5}

Columbia agar +5% Sheep blood plates and Mannitol-salt agar plates were purchased from Biomerieux (43041, 43671). Swabs were dipped in PBS, lesional skin of mice were swabbed and the swabs were directly inoculated on the plates. Plates were incubated at 37C for 24 hours. DNA was isolated from single colonies grown on blood agar plates, and PCR was carried. Oligo sequences are included in [Table S1](#mmc1){ref-type="supplementary-material"}. USA300 *S. aureus* strain and a specimen from a nearby hospital were used as positive controls. To measure CFUs of *S. aureus*, we performed a standard plate count method. Briefly, skin swabs from the lesional skin of *JunB*^*Δep*^ mice (1 cm^2^), and equivalent area in control mice were placed into 1 mL of PBS, and serial dilutions were prepared. 200 μL of each dilution was transferred on blood agar plates, and colonies were counted after a 1-day incubation. CFUs were calculated by dividing the number of colonies per plate by the dilution factor.

### Transcriptomic analysis {#sec4.4.6}

Samples of 1ug of total RNA were used. Average sample RNA integrity number was 7.75 (range 7-9.2) when assayed on Agilent 2100 Bioanalyzer. PolyA+ fraction was purified and randomly fragmented, converted to double stranded cDNA and processed through subsequent enzymatic treatments of end-repair, dA-tailing, and ligation to adapters as in Illumina's "TruSeq Stranded mRNA Sample Preparation Part \# 15031047 Rev. D" kit (this kit incorporates dUTP during 2^nd^ strand cDNA synthesis, which implies that only the cDNA strand generated during 1^st^ strand syntesis is eventually sequenced). Adaptor-ligated library was completed by PCR with Illumina PE primers. The resulting purified cDNA library was applied to an Illumina flow cell for cluster generation and sequenced on an Illumina instrument (see below) by following manufacturer's protocol. Sequencing reads were analyzed with the next*presso* pipeline ([@bib18]), as follows: sequencing quality was checked with FastQC v0.11.0 (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>). Reads were aligned to the mouse genome (NCBI37/mm9) with TopHat-2.0.10 ([@bib62]) using Bowtie 1.0.0 ([@bib33]) and SAMtools 0.1.19 ([@bib36]), allowing 2 mismatches and 20 multihits. Differential expression was tested with DESeq2 ([@bib38]), using the mouse NCBI37/mm9 transcript annotations from <https://ccb.jhu.edu/software/tophat/igenomes.shtml>. GSEAPreranked ([@bib60]) was used to perform gene set enrichment analysis of the described gene signatures on a pre-ranked gene list, setting 1000 gene set permutations.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Two-tailed students's t test after Shapiro-Wilk normality test was used to determine statistical significance. Linear regression analyses was used for the correlation study in [Figure 2](#fig2){ref-type="fig"}E. One-way ANOVA with multiple-comparisons was used for [Figures 4](#fig4){ref-type="fig"}C and [6](#fig6){ref-type="fig"}B and [7](#fig7){ref-type="fig"}C.

Data and Code Availability {#sec4.6}
--------------------------

Data from RNA sequencing analysis has been deposited to GEO with accession number GEO: [GSE136657](ncbi-geo:GSE136657){#intref0055}.
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